fludarabine has been researched along with Hepatic Veno Occlusive Disease in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanda, Y | 1 |
| Bajwa, RP; Rose, MJ; Woods, G | 1 |
| Avni, B; Grisariu, S; Or, R; Resnick, IB; Shapira, MY; Stepensky, P; Tsirigotis, PD | 1 |
| Drozdinsky, G; Erlich, O; Gorelik, N; Lamdan, R; Natsheh, J; Or, R; Simanovsky, N; Stepensky, P; Weintraub, M | 1 |
| Bermúdez, A; Caballero, MD; Cabrero, M; Conde, E; De La Serna, J; Gómez, V; Lahuerta, JJ; Moraleda, JM; Perez, SG; Sanz, G; Sanz, J; Serrano, D; Vallejo, C | 1 |
| Artz, A; Bredeson, C; Burkart, J; DiPersio, J; Fernandez, HF; Kamishohara, M; Le-Rademacher, J; Mehta, J; Mineishi, S; Nakamura, Y; Pasquini, MC; Ratanatharathorn, V; Sobecks, R; Zhu, X | 1 |
| Artz, AS; Del Cerro, P; Godley, LA; Hart, J; Horowitz, S; Innocenti, F; Larson, RA; O'Donnell, PH; Odenike, OM; Pai, RK; Stock, W; Undevia, SD; Van Besien, K | 1 |
| Artz, AS; Hart, J; O'Donnell, PH; Pai, RK; van Besien, K | 1 |
| Fujiwara, M; Hori, A; Kami, M; Kanda, Y; Komatsu, T; Koyama, R; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Murashige, N; Seki, K; Tanaka, Y; Taniguchi, S; Wake, A; Yuji, K | 1 |
| Forman, SJ; Kogut, N; Krishnan, A; Nademanee, A; Nakamura, R; Patane, K; Popplewell, L; Rodriguez, R; Ruel, N; Sarkodee-Adoo, C; Smith, E; Zain, J | 1 |
| Kabisch, H; Kröger, N; Krüger, W; Renges, H; Schetelig, J; Schrum, J; Siegert, W; Stute, N; Zabelina, T; Zander, AR | 1 |
1 review(s) available for fludarabine and Hepatic Veno Occlusive Disease
| Article | Year |
|---|---|
Reduced intensity transplantation for congenital amegakaryocytic thrombocytopenia: report of a case and review of the literature.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Blood Platelets; Congenital Bone Marrow Failure Syndromes; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infant; Melphalan; Methylprednisolone; Mucositis; Neutrophils; Thrombocytopenia; Transplantation Conditioning; Vidarabine | 2014 |
3 trial(s) available for fludarabine and Hepatic Veno Occlusive Disease
| Article | Year |
|---|---|
Is pharmacokinetic guidance a must in busulfan regimens?
Topics: Area Under Curve; Busulfan; Cyclophosphamide; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Male; Randomized Controlled Trials as Topic; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2018 |
Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS.
Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Histocompatibility; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mucositis; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2016 |
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Busulfan; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Immunosuppressive Agents; Incidence; Male; Metabolic Clearance Rate; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2010 |
7 other study(ies) available for fludarabine and Hepatic Veno Occlusive Disease
| Article | Year |
|---|---|
Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen.
Topics: Adolescent; Adult; Aged; Allografts; Antilymphocyte Serum; Female; Hepatic Veno-Occlusive Disease; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine | 2014 |
Improved Outcomes of Hematopoietic Stem Cell Transplantation in Patients With Infantile Malignant Osteopetrosis Using Fludarabine-Based Conditioning.
Topics: Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Hypercalcemia; Infant; Infant, Newborn; Male; Osteopetrosis; Postoperative Complications; Tissue Donors; Tissue Survival; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2016 |
Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infant; Male; Middle Aged; Myeloablative Agonists; Pneumonia; Prospective Studies; Seizures; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Area Under Curve; Biopsy; Busulfan; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Liver; Male; Middle Aged; Stem Cell Transplantation; Time Factors; Vidarabine | 2012 |
Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Busulfan; Chemical and Drug Induced Liver Injury; Cholangitis; Cord Blood Stem Cell Transplantation; Cyclosporine; Female; Hematologic Diseases; Hematologic Neoplasms; Hepatic Veno-Occlusive Disease; Humans; Hyperbilirubinemia; Immunosuppressive Agents; Incidence; Infant, Newborn; Liver Diseases; Liver Function Tests; Male; Melphalan; Middle Aged; Postoperative Complications; Risk Factors; Tacrolimus; Tissue Donors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2006 |
Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Busulfan; Cause of Death; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Infections; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Proportional Hazards Models; Reoperation; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2006 |
A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antilymphocyte Serum; Bone Marrow; Busulfan; Cell Count; Chromosomes, Human, Pair 7; Cyclophosphamide; Disease-Free Survival; Feasibility Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Histocompatibility; Humans; Infections; Karyotyping; Methotrexate; Middle Aged; Monosomy; Myelodysplastic Syndromes; Recurrence; Survival Rate; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2001 |